Remove 2018 Remove FDA Remove Labelling
article thumbnail

Opinion: Diagnostic tests for rare conditions present a mathematical conundrum

STAT

Even before the Covid pandemic, a 2018 paper reported that new genetic tests, many of them for increasingly rare conditions, were being released at the rate of 10 a day. You can now avail yourself of noninvasive diagnostics that claim to screen for rare birth defects, cancer-associated mutations, and even Alzheimer’s.

Labelling 131
article thumbnail

FDA approves Zepbound for weight loss

The Checkup by Singlecare

Food and Drug Administration (FDA) just approved Zepbound (tirzepatide) for chronic weight management. The injectable medication is a new version of Eli Lilly’s Mounjaro, which is approved by the FDA to control blood sugar in people with Type 2 diabetes. Zepbound, on the other hand, has been FDA-approved for weight loss.

FDA 120
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Failed trial nixes another FDA approval, this time for BMS’ Istodax

pharmaphorum

The HDAC inhibitor was given an accelerated approval by the FDA as a second-line PTCL therapy on the strength of overall response data, but a phase 3 study comparing Istodax to first-line chemotherapy showed no improvement on progression-free survival (PFS).

FDA 98
article thumbnail

GSK’s Benlysta claims first FDA okay for lupus kidney damage

pharmaphorum

GlaxoSmithKline’s Benlysta has been on the market for almost a decade, but it still has some tricks up its sleeve – it’s just become the first and only FDA-approved treatment for lupus nephritis. AstraZeneca wasn’t so fortunate with its anifrolumab candidate, which flunked a pivotal trial in SLE in 2018, but still thinks it has potential.

FDA 99
article thumbnail

EHA21: Sanofi builds case for rare disease drug sutimlimab after FDA rejection

pharmaphorum

Sanofi’s hopes of a speedy approval of first-in-class C1s inhibitor sutimlimab in rare disorder cold agglutinin disease (CAD) were dashed by the FDA, but new phase 3 data keep the drugmaker on track for a resubmission before year-end. At the moment CAD is managed using off-label therapies, including rituximab and corticosteroid drugs.

FDA 96
article thumbnail

8 common off-label uses of SSRIs

The Checkup by Singlecare

From 2015 to 2018, 13.2% Since Prozac (fluoxetine) was approved by the FDA in 1987, selective serotonin reuptake inhibitors (SSRIs) have been the most commonly prescribed antidepressants on the market. This is called off-label prescribing , and SSRIs rank among the top use cases for off-label use.

article thumbnail

Bad news for Pfizer as blockbuster Xeljanz flunks safety study

pharmaphorum

JAK inhibitor Xeljanz is one of Pfizer’s top-selling drugs, despite a ‘black box’ warning for blood clots and cancers added to its label in 2019. Now, a study designed to prove its safety has achieved the opposite. Xeljanz isn’t the only drug in the class to be affected by toxicity concerns of course.

Labelling 135